Dow Dull Except for...
Health Care: Drugs
Celsion Corporation (CLSN: NASDAQ)
$0.98 -0.03 | -2.97%
05/20/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 1.01 |
| 52 Week High | 9.44 |
| 52 Week Low | 0.75 |
| Avg. Daily Vol. (Mil) | 2.27 |
| Beta (3 year) | 1.40 |
| Share Related Items | |
| Mkt Cap (Mil) | 52.13 |
| Shares Out (Mil) | 51.61 |
| Float (Mil) | 47.71 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 6.00 |
| Current Ratio | 6.10 |
| LT Debt/ Equity | 0.10 |
| Total Debt / Equity | 0.16 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 417.03 |
| Price/Book | 1.61 |
| Price/Cash Flow | -1.70 |
| Per Share Data | |
| Earnings | -0.69 |
| Sales | 0.00 |
| Book Value | 0.63 |
| Cash Flow | -0.61 |
| Business Summary | |
|---|---|
| Celsion Corporation is an innovative oncology drug development company focused on the development of treatments for those suffering with difficult to treat forms of cancer. | |
| General Information | |
| 997 Lenox Drive
Suite 100 Lawrenceville, NJ 08648 |
|
| www.celsion.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 19 | |
| CEO: Michael H. Tardugno | |
| Short Interest | |
| Current Month (Mil) | 6.94 |
| Previous Month (Mil) | 6.67 |
| Short Interest Ratio (Days) | 5.00 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -56.80 |
| Return on Investments | -76.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with CLSN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- ContributorBreakout Stocks Of The Week...
- UserWatch
- UserBIO
- ContributorStocks Under-$10 Moving Hig...
- Contributor22 Biopharma Stocks With Br...
- ContributorTop 5 Small-Cap Stocks to C...
- ContributorStocks Under-$10 Moving Hig...
Latest CLSN Headlines from TheStreet
- The 5 Dumbest Things on Wall Street This Week 04.26.13 | 07:04 am
- 5 Dumbest Things on Wall Street
04.26.13 | 07:04 am - Celsion's Shameless Spin Job (Update) 04.23.13 | 05:04 pm
- Why This Fund Manager Is Short Ziopharm 03.22.13 | 07:03 am
- 4 Stocks Under $10 Spiking Higher 03.08.13 | 07:03 am
- Biotech Stock Mailbag: Northwest Bio, Amarin, Titan Pharma 02.15.13 | 06:02 am
- Ziopharm's Sarcoma Study And The Feuerstein-Ratain Rule 02.05.13 | 06:02 am
- Stocks Surge After January Jobs Report; Dow Eclipses 14,000 02.01.13 | 02:02 pm
- Biotech Stock Mailbag: Celsion, Navidea, AP Pharma, Sarepta 02.01.13 | 07:02 am
- Seeking Alpha Author Used Multiple Aliases to Tout Biotech Stocks 01.28.13 | 06:01 am
Press Releases for CLSN
- Celsion Corporation To Hold Year-End 2012 Financial Results Conference Call On Monday, March 18, 2013 - PR Newswire 03.12.13 | 08:03 am
- Celsion Corporation Announces $15 Million Registered Direct Offering - PR Newswire 02.22.13 | 09:02 am
- Celsion Corporation Provides An Update Regarding ThermoDox® Agreements With Zhejiang HISUN Pharmaceutical Company For China - PR Newswire 02.05.13 | 06:02 pm
- Celsion Announces Results Of Phase III HEAT Study Of ThermoDox® In Primary Liver Cancer - PR Newswire 01.31.13 | 07:01 am
- Celsion Corporation To Host Conference Call And Webcast On January 31, 2013 At 8:00 AM EST To Present Top-Line Data From Its Pivotal Phase III HEAT Study - PR Newswire 01.30.13 | 04:01 pm
- Celsion Corporation And Zhejiang Hisun Pharmaceutical Company Enter Into Technology Development Agreement For ThermoDox® For The Greater China Territory - PR Newswire 01.22.13 | 08:01 am
- Celsion Corporation Announces Completion Of $5.1 Million Registered Direct Offering - PR Newswire 01.21.11 | 03:01 pm
Partner Headlines for CLSN
- 3 Biotechs And The Feuerstein-Ratain Rule - Seeking Alpha 04.09.13 | 09:04 am
- A 2013 Diversified Bullish Portfolio In 10 Positions - Seeking Alpha 02.28.13 | 09:02 am
- After Phase III Failure, Celsion Is Still Worthless - Seeking Alpha 02.12.13 | 09:02 am
- Is Delcath The Post-Celsion Play On Liver Cancer? - Seeking Alpha 02.04.13 | 09:02 am
- Celsion Stock Blown Apart On Thermodox Phase III Data - Seeking Alpha 02.02.13 | 09:02 am
- Biotech Weekly Recap: Loads Of Bullishness, 2 Giant Rallies, And Selling - Seeking Alpha 12.02.12 | 09:12 am
- 5 Healthcare Companies With Recent Insider Buying - Seeking Alpha 11.18.12 | 09:11 am
- Pre-Market Earnings Report for November 12, 2012 : DHI, CYD, BZH, CLSN, RRST, CTIB - NASDAQ 11.09.12 | 09:11 pm
- 4 Biotechs That Just Got Mauled By Bears - Seeking Alpha 10.10.12 | 09:10 am
- Weekly CEO Buys Highlight: NIHD, RENT, VTNC, MDW - NASDAQ 09.24.12 | 02:09 pm
